Heterocyclic compounds as FGFR inhibitors
US10752631B2 · kind B2 · utility
0Cited by
1References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 27, 2017 |
| Grant date | Aug 25, 2020 |
| Priority date | — |
| Expiry date | Aug 7, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the same, a preparation method thereof, and a use thereof as a fibroblast growth factor receptor (FGFR) inhibitor. The compound is a heterocyclic compound as shown in Formula I, or a pharmaceutically acceptable salt, a prodrug, a solvate, a polymorph, an isomer, or a stable isotopic derivative thereof. The present invention further relates to a method of treating or preventing a FGFR-mediated disease, such as cancer, using the compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.